COVID-19-associated anosmia: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(12 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{COVID-19}}
{{SI}}


{{CMG}}; {{AE}}[[User:MoisesRomo|Moises Romo M.D.]]
{{CMG}}; {{AE}}[[User:MoisesRomo|Moises Romo M.D.]] {{Fs}}


{{SK}}[[anosmia]], olfactory dysfunction, [[SARS-CoV-2]], [[dysgeusia]]  
{{SK}} [[anosmia]], olfactory dysfunction, [[SARS-CoV-2]], [[dysgeusia]]  


==Overview==
==Overview==
Line 174: Line 174:
**Genetic susceptibility
**Genetic susceptibility
*Susceptibility to [[COVID-19]] [[infection]] is influenced to some degree by the [[Host (biology)|host]] [[genotype]], making a 47-fold [[heritability]] for [[anosmia]].<ref name="pmid32563019" /><ref name="WilliamsFreydin2020">{{cite journal|last1=Williams|first1=Frances MK|last2=Freydin|first2=Maxim|last3=Mangino|first3=Massimo|last4=Couvreur|first4=Simon|last5=Visconti|first5=Alessia|last6=Bowyer|first6=Ruth CE|last7=Le Roy|first7=Caroline I|last8=Falchi|first8=Mario|last9=Sudre|first9=Carole|last10=Davies|first10=Richard|last11=Hammond|first11=Christopher|last12=Menni|first12=Cristina|last13=Steves|first13=Claire|last14=Spector|first14=Tim|year=2020|doi=10.1101/2020.04.22.20072124}}</ref>
*Susceptibility to [[COVID-19]] [[infection]] is influenced to some degree by the [[Host (biology)|host]] [[genotype]], making a 47-fold [[heritability]] for [[anosmia]].<ref name="pmid32563019" /><ref name="WilliamsFreydin2020">{{cite journal|last1=Williams|first1=Frances MK|last2=Freydin|first2=Maxim|last3=Mangino|first3=Massimo|last4=Couvreur|first4=Simon|last5=Visconti|first5=Alessia|last6=Bowyer|first6=Ruth CE|last7=Le Roy|first7=Caroline I|last8=Falchi|first8=Mario|last9=Sudre|first9=Carole|last10=Davies|first10=Richard|last11=Hammond|first11=Christopher|last12=Menni|first12=Cristina|last13=Steves|first13=Claire|last14=Spector|first14=Tim|year=2020|doi=10.1101/2020.04.22.20072124}}</ref>
*To view the epidemiology and demographics of COVID-19, [[COVID-19 risk factors|click here]].
*To view the risk factors of COVID-19, [[COVID-19 risk factors|click here]].


==Screening==
==Screening==


*A [[Screening (medicine)|screening]] strategy, duly validated for [[Olfaction|olfactory]] [[disfunction]] in [[COVID-19]], consists of carrying out specific questionnaires, such as the ''Questionnaire for Olfactory Disfunction''.<ref name="pmid32466862" /><ref name="pmid26384780">{{cite journal |vauthors=Nguyen DT, Rumeau C, Gallet P, Jankowski R |title=Olfactory exploration: State of the art |journal=Eur Ann Otorhinolaryngol Head Neck Dis |volume=133 |issue=2 |pages=113–8 |date=April 2016 |pmid=26384780 |doi=10.1016/j.anorl.2015.08.038 |url=}}</ref><ref name="pmid22566102">{{cite journal |vauthors=Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V |title=Olfaction-associated quality of life in chronic rhinosinusitis: adaptation and validation of an olfaction-specific questionnaire |journal=Laryngoscope |volume=122 |issue=7 |pages=1450–4 |date=July 2012 |pmid=22566102 |doi=10.1002/lary.23349 |url=}}</ref>
*A [[Screening (medicine)|screening]] strategy, duly validated for [[Olfaction|olfactory]] [[disfunction]] in [[COVID-19]], consists of carrying out specific questionnaires, such as the ''Questionnaire for Olfactory Disfunction''.<ref name="pmid32466862" /><ref name="pmid26384780">{{cite journal |vauthors=Nguyen DT, Rumeau C, Gallet P, Jankowski R |title=Olfactory exploration: State of the art |journal=Eur Ann Otorhinolaryngol Head Neck Dis |volume=133 |issue=2 |pages=113–8 |date=April 2016 |pmid=26384780 |doi=10.1016/j.anorl.2015.08.038 |url=}}</ref><ref name="pmid22566102">{{cite journal |vauthors=Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V |title=Olfaction-associated quality of life in chronic rhinosinusitis: adaptation and validation of an olfaction-specific questionnaire |journal=Laryngoscope |volume=122 |issue=7 |pages=1450–4 |date=July 2012 |pmid=22566102 |doi=10.1002/lary.23349 |url=}}</ref>
*Several [[ENT]] societies in the United Kingdom and the United States, have advised to treat [[anosmia]] marker of [[SARS-CoV-2]] [[infection]].<ref name=":0">{{Cite journal|last=Robert Pellegrin, Keiland W. Cooper, Antonella Di Pizio, Paule V. Joseph, Surabhi Bhutani, Valentina Parma|first=|date=2020|title=Corona Viruses and the Chemical Senses:
*Several [[ENT]] societies in the United Kingdom and the United States, have advised treating [[anosmia]] marker of [[SARS-CoV-2]] [[infection]].<ref name=":0">{{Cite journal|last=Robert Pellegrin, Keiland W. Cooper, Antonella Di Pizio, Paule V. Joseph, Surabhi Bhutani, Valentina Parma|first=|date=2020|title=Corona Viruses and the Chemical Senses:
Past, Present, and Future|url=|journal=Oxford University|volume=|pages=|via=}}</ref><ref name="urlwww.entuk.org">{{cite web |url=https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf |title=www.entuk.org |format= |work= |accessdate=}}</ref><ref name="urlAAO-HNSF 2020 Annual Meeting & OTO Experience | American Academy of Otolaryngology-Head and Neck Surgery">{{cite web |url=https://www.entnet.org/content/aao-hnsf-2020-annual-meeting-oto-experience |title=AAO-HNSF 2020 Annual Meeting & OTO Experience &#124; American Academy of Otolaryngology-Head and Neck Surgery |format= |work= |accessdate=}}</ref>
Past, Present, and Future|url=|journal=Oxford University|volume=|pages=|via=}}</ref><ref name="urlwww.entuk.org">{{cite web |url=https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf |title=www.entuk.org |format= |work= |accessdate=}}</ref><ref name="urlAAO-HNSF 2020 Annual Meeting & OTO Experience | American Academy of Otolaryngology-Head and Neck Surgery">{{cite web |url=https://www.entnet.org/content/aao-hnsf-2020-annual-meeting-oto-experience |title=AAO-HNSF 2020 Annual Meeting & OTO Experience &#124; American Academy of Otolaryngology-Head and Neck Surgery |format= |work= |accessdate=}}</ref>
* The [[American Academy of Otolaryngology]] (AAO) proposed for [[anosmia]], [[hyposmia]], and [[dysgeusia]] to be added to the list of [[Screening test|screening]] tools for [[COVID-19]] in otherwise [[asymptomatic]] individuals.<ref name="urlAAO-HNSF 2020 Annual Meeting & OTO Experience | American Academy of Otolaryngology-Head and Neck Surgery" /><ref name=":0" />
* The [[American Academy of Otolaryngology]] (AAO) proposed for [[anosmia]], [[hyposmia]], and [[dysgeusia]] to be added to the list of [[Screening test|screening]] tools for [[COVID-19]] in otherwise [[asymptomatic]] individuals.<ref name="urlAAO-HNSF 2020 Annual Meeting & OTO Experience | American Academy of Otolaryngology-Head and Neck Surgery" /><ref name=":0" />
*In the absence of available solid data, the recommendation should be to perform nasal swabs on any patient with recent onset [[anosmia]], duly assessed.<ref name="pmid32466862" />
*In the absence of available solid data, the recommendation should be to perform nasal swabs on any patient with recent-onset [[anosmia]], duly assessed.<ref name="pmid32466862" />
*To view screening for COVID-19, [[COVID-19 screening|click here]].<br />
*To view screening for COVID-19, [[COVID-19 screening|click here]].<br />


Line 191: Line 191:
* Approximately 82% of patients with [[anosmia]] related to [[COVID-19]] recover within 2 weeks and 98% of them within 28 days.<ref name="pmid32563019" /><ref name="pmid323055632" /><ref name="pmid32279441">{{cite journal |vauthors=Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS |title=Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms |journal=Int Forum Allergy Rhinol |volume= |issue= |pages= |date=April 2020 |pmid=32279441 |pmc=7262089 |doi=10.1002/alr.22579 |url=}}</ref>
* Approximately 82% of patients with [[anosmia]] related to [[COVID-19]] recover within 2 weeks and 98% of them within 28 days.<ref name="pmid32563019" /><ref name="pmid323055632" /><ref name="pmid32279441">{{cite journal |vauthors=Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS |title=Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms |journal=Int Forum Allergy Rhinol |volume= |issue= |pages= |date=April 2020 |pmid=32279441 |pmc=7262089 |doi=10.1002/alr.22579 |url=}}</ref>
*The intensity and duration of the [[Olfaction|olfactory]] [[disfunction]] associated to [[COVID-19]], is highly variable depending on the capacity and rate of regeneration of the neuroepitielium.<ref name="pmid32466862" />
*The intensity and duration of the [[Olfaction|olfactory]] [[disfunction]] associated to [[COVID-19]], is highly variable depending on the capacity and rate of regeneration of the neuroepitielium.<ref name="pmid32466862" />
*A recent review by JAMA showed that 96% of the patients recover from [[anosmia]] within one year of its onset. At 6 months, 85% of the patients recovered from [[anosmia]]. [[Parosmia]] was not evaluated, and it can be potentially more debilitating for patients.<ref name="pmid34165581">{{cite journal| author=Renaud M, Thibault C, Le Normand F, Mcdonald EG, Gallix B, Debry C | display-authors=etal| title=Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis. | journal=JAMA Netw Open | year= 2021 | volume= 4 | issue= 6 | pages= e2115352 | pmid=34165581 | doi=10.1001/jamanetworkopen.2021.15352 | pmc=8226421 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34165581  }} </ref>
*To view natural history, complications, and prognosis of COVID-19, [[COVID-19 natural history, complications and prognosis|click here]].
*To view natural history, complications, and prognosis of COVID-19, [[COVID-19 natural history, complications and prognosis|click here]].


Line 210: Line 211:
*[[Anosmia]] occurs more commonly after the onset of other [[symptoms]]. In a study involving 1325 participants with [[anosmia]] (with no confirmatory [[COVID-19 diagnostic study of choice|COVID-19 test]]), 13% reported [[anosmia]] before their onset, 38.4% at the same time, and in 48.6% after the onset of [[symptoms]].<ref name="pmid32277751" />
*[[Anosmia]] occurs more commonly after the onset of other [[symptoms]]. In a study involving 1325 participants with [[anosmia]] (with no confirmatory [[COVID-19 diagnostic study of choice|COVID-19 test]]), 13% reported [[anosmia]] before their onset, 38.4% at the same time, and in 48.6% after the onset of [[symptoms]].<ref name="pmid32277751" />
* A study reports that [[anosmia]] typically developes after 4.4 days of [[COVID-19]] [[infection]].<ref name="pmid323055632">{{cite journal |vauthors=Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V, Zayet S |title=Features of anosmia in COVID-19 |journal=Med Mal Infect |volume= |issue= |pages= |date=April 2020 |pmid=32305563 |pmc=7162775 |doi=10.1016/j.medmal.2020.04.006 |url=}}</ref><ref name="pmid32563019" />
* A study reports that [[anosmia]] typically developes after 4.4 days of [[COVID-19]] [[infection]].<ref name="pmid323055632">{{cite journal |vauthors=Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V, Zayet S |title=Features of anosmia in COVID-19 |journal=Med Mal Infect |volume= |issue= |pages= |date=April 2020 |pmid=32305563 |pmc=7162775 |doi=10.1016/j.medmal.2020.04.006 |url=}}</ref><ref name="pmid32563019" />
'''Common Symptoms'''
* Common symptoms accompanying [[anosmia]] related to [[COVID-19]] are:
** [[Fever]]
** [[Headache]]
** [[Nausea]]/ [[vomiting]]
** [[Irritability]]
** [[Malaise]]
** [[Neck stiffness]]
** Light sensitivity/ [[photophobia]]
'''Less Common Symptoms'''
* Less common symptoms accompanying [[anosmia]] related to [[COVID-19]] are:
** [[Myalgias]]
** [[Confusion]]
** [[Seizures]] (with concomitant [[encephalitis]])
*To view the history and symptoms of COVID-19, [[COVID-19 history and symptoms|click here]].
*To view the history and symptoms of COVID-19, [[COVID-19 history and symptoms|click here]].


===Physical Examination===
===Physical Examination===
===== HEENT =====


*[[Physical examination]] using kits of different [[Olfaction|olfactory]] stimuli may disclose conductive, sensorineural, or mixed [[Olfaction|olfactory]] disfunction.<ref name="pmid32466862" />
*[[Physical examination]] using kits of different [[Olfaction|olfactory]] stimuli may disclose conductive, sensorineural, or mixed [[Olfaction|olfactory]] disfunction.<ref name="pmid32466862" />
Line 236: Line 258:
===X-ray===
===X-ray===


*[[X-ray]] imaging to the [[nasal cavity]] and [[sinus]] (Cadwell and Waters projections) does not demonstrate any typical finidings in patients with [[anosmia]] due to [[COVID-19]], but may be used to exclude other causes
*[[X-ray]] imaging to the [[nasal cavity]] and [[sinus]] (Cadwell and Waters projections) does not demonstrate any typical findings in patients with [[anosmia]] due to [[COVID-19]], but may be used to exclude other causes
* To view the x-ray finidings on COVID-19, [[COVID-19 x ray|click here]].<br />
* To view the x-ray finidings on COVID-19, [[COVID-19 x ray|click here]].<br />


Line 251: Line 273:
===MRI===
===MRI===


*[[MRI]] imaging to the [[nasal cavity]] and [[sinus]] does not demonstrate any typical finidings in patients with anosmia due to COVID-19, but may be used to exclude other causes.
*[[MRI]] imaging to the [[nasal cavity]] and [[sinus]] does not demonstrate any typical findings in patients with anosmia due to COVID-19 but may be used to exclude other causes.
* To view the MRI findings on COVID-19, [[COVID-19 MRI|click here]].<br />
* To view the MRI findings on COVID-19, [[COVID-19 MRI|click here]].<br />


===Other Imaging Findings===
===Other Imaging Findings===


*[[Ultrasound]] imaging to the [[nasal cavity]] and [[sinus]] does not demonstrate any typical finidings in patients with anosmia due to [[COVID-19]], but may be used to exclude other causes.
*[[Ultrasound]] imaging to the [[nasal cavity]] and [[sinus]] does not demonstrate any typical findings in patients with anosmia due to [[COVID-19]] but may be used to exclude other causes.
* To view other imaging findings on COVID-19, [[COVID-19 other imaging findings|click here]].<br />
* To view other imaging findings on COVID-19, [[COVID-19 other imaging findings|click here]].<br />


Line 266: Line 288:
===Medical Therapy===
===Medical Therapy===


* [[Oral steroids]] may be useful in patients with [[anosmia]] related to [[COVID-19]] after careful discusion of [[risks]] and benefits, when duration exceeds 2 weeks.<ref name="pmid322777512" /> However, current [[World Health Organization|World Health Organization (WHO)]] guidelines advice to avoid the use of [[Oral steroids|systemic steroids]] when possible.<ref name="urlCoronavirus disease (COVID-19)">{{cite web |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019 |title=Coronavirus disease (COVID-19) |format= |work= |accessdate=}}</ref><ref name="pmid322777512" /> [[Dosage]] has not been clarified by the source, but [[doses]] of 40–60 mg/day for 10–14 days of oral [[prednisolone]] have been shown to improve the mean [[Olfaction|olfactory]] recognition threshold in other causes of [[viral]] [[anosmia]].<ref name="pmid8560170">{{cite journal |vauthors=Ikeda K, Sakurada T, Suzaki Y, Takasaka T |title=Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease |journal=Rhinology |volume=33 |issue=3 |pages=162–5 |date=September 1995 |pmid=8560170 |doi= |url=}}</ref>
* [[Oral steroids]] may be useful in patients with [[anosmia]] related to [[COVID-19]] after careful evaluation of [[risks]] and benefits, when duration exceeds 2 weeks. However, current [[World Health Organization|World Health Organization (WHO)]] guidelines advice to avoid the use of [[Oral steroids|systemic steroids]] when possible.<ref name="urlCoronavirus disease (COVID-19)">{{cite web |url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019 |title=Coronavirus disease (COVID-19) |format= |work= |accessdate=}}</ref><ref name="pmid322777512">{{cite journal |vauthors=Hopkins C, Surda P, Kumar N |title=Presentation of new onset anosmia during the COVID-19 pandemic |journal=Rhinology |volume=58 |issue=3 |pages=295–298 |date=June 2020 |pmid=32277751 |doi=10.4193/Rhin20.116 |url=}}</ref> <ref name="pmid8560170">{{cite journal |vauthors=Ikeda K, Sakurada T, Suzaki Y, Takasaka T |title=Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease |journal=Rhinology |volume=33 |issue=3 |pages=162–5 |date=September 1995 |pmid=8560170 |doi= |url=}}</ref><ref name="pmid8560170" /><ref name="pmid319501562">{{cite journal |vauthors=Yan CH, Rathor A, Krook K, Ma Y, Rotella MR, Dodd RL, Hwang PH, Nayak JV, Oyesiku NM, DelGaudio JM, Levy JM, Wise J, Wise SK, Patel ZM |title=Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial |journal=Neurosurgery |volume= |issue= |pages= |date=January 2020 |pmid=31950156 |doi=10.1093/neuros/nyz559 |url=}}</ref><ref name="pmid31950156">{{cite journal |vauthors=Yan CH, Rathor A, Krook K, Ma Y, Rotella MR, Dodd RL, Hwang PH, Nayak JV, Oyesiku NM, DelGaudio JM, Levy JM, Wise J, Wise SK, Patel ZM |title=Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial |journal=Neurosurgery |volume= |issue= |pages= |date=January 2020 |pmid=31950156 |doi=10.1093/neuros/nyz559 |url=}}</ref><ref name="RedenLill2012">{{cite journal|last1=Reden|first1=Jens|last2=Lill|first2=Katja|last3=Zahnert|first3=Thomas|last4=Haehner|first4=Antje|last5=Hummel|first5=Thomas|title=Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A: A double-blind, placebo-controlled, randomized clinical trial|journal=The Laryngoscope|volume=122|issue=9|year=2012|pages=1906–1909|issn=0023852X|doi=10.1002/lary.23405}}</ref><ref name="pmid12439184">{{cite journal |vauthors=Hummel T, Heilmann S, Hüttenbriuk KB |title=Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract |journal=Laryngoscope |volume=112 |issue=11 |pages=2076–80 |date=November 2002 |pmid=12439184 |doi=10.1097/00005537-200211000-00031 |url=}}</ref><ref name="pmid124391842">{{cite journal |vauthors=Hummel T, Heilmann S, Hüttenbriuk KB |title=Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract |journal=Laryngoscope |volume=112 |issue=11 |pages=2076–80 |date=November 2002 |pmid=12439184 |doi=10.1097/00005537-200211000-00031 |url=}}</ref><ref name="pmid28040824">{{cite journal |vauthors=Sorokowska A, Drechsler E, Karwowski M, Hummel T |title=Effects of olfactory training: a meta-analysis |journal=Rhinology |volume=55 |issue=1 |pages=17–26 |date=March 2017 |pmid=28040824 |doi=10.4193/Rhin16.195 |url=}}</ref><ref name="pmid32466862" /><ref name="pmid15563908">{{cite journal |vauthors=Seiden AM |title=Postviral olfactory loss |journal=Otolaryngol. Clin. North Am. |volume=37 |issue=6 |pages=1159–66 |date=December 2004 |pmid=15563908 |doi=10.1016/j.otc.2004.06.007 |url=}}</ref>
* Olfactory training suggest small to moderate benefit for patients with post-viral [[Olfaction|olfactory]] [[dysfunction]].<ref name="pmid322777512">{{cite journal |vauthors=Hopkins C, Surda P, Kumar N |title=Presentation of new onset anosmia during the COVID-19 pandemic |journal=Rhinology |volume=58 |issue=3 |pages=295–298 |date=June 2020 |pmid=32277751 |doi=10.4193/Rhin20.116 |url=}}</ref>
*[[Dosage]] has not been clarified by the source, but [[doses]] of 40–60 mg/day for 10–14 days of oral [[prednisolone]] have been shown to improve the mean [[Olfaction|olfactory]] recognition threshold in other causes of [[viral]] [[anosmia]].
* [[Alpha lipoic acid]] (600 mg/day),<ref name="pmid8560170" /><ref name="pmid12439184">{{cite journal |vauthors=Hummel T, Heilmann S, Hüttenbriuk KB |title=Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract |journal=Laryngoscope |volume=112 |issue=11 |pages=2076–80 |date=November 2002 |pmid=12439184 |doi=10.1097/00005537-200211000-00031 |url=}}</ref><ref name="pmid124391842">{{cite journal |vauthors=Hummel T, Heilmann S, Hüttenbriuk KB |title=Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract |journal=Laryngoscope |volume=112 |issue=11 |pages=2076–80 |date=November 2002 |pmid=12439184 |doi=10.1097/00005537-200211000-00031 |url=}}</ref> [[omega-3]] supplementation (2000mg/day),<ref name="pmid8560170" /><ref name="pmid319501562">{{cite journal |vauthors=Yan CH, Rathor A, Krook K, Ma Y, Rotella MR, Dodd RL, Hwang PH, Nayak JV, Oyesiku NM, DelGaudio JM, Levy JM, Wise J, Wise SK, Patel ZM |title=Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial |journal=Neurosurgery |volume= |issue= |pages= |date=January 2020 |pmid=31950156 |doi=10.1093/neuros/nyz559 |url=}}</ref><ref name="pmid31950156">{{cite journal |vauthors=Yan CH, Rathor A, Krook K, Ma Y, Rotella MR, Dodd RL, Hwang PH, Nayak JV, Oyesiku NM, DelGaudio JM, Levy JM, Wise J, Wise SK, Patel ZM |title=Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial |journal=Neurosurgery |volume= |issue= |pages= |date=January 2020 |pmid=31950156 |doi=10.1093/neuros/nyz559 |url=}}</ref> and intranasal [[Vitamin A derivatives|vitamin A]] (10,000 U/day)<ref name="pmid8560170" /><ref name="RedenLill2012">{{cite journal|last1=Reden|first1=Jens|last2=Lill|first2=Katja|last3=Zahnert|first3=Thomas|last4=Haehner|first4=Antje|last5=Hummel|first5=Thomas|title=Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A: A double-blind, placebo-controlled, randomized clinical trial|journal=The Laryngoscope|volume=122|issue=9|year=2012|pages=1906–1909|issn=0023852X|doi=10.1002/lary.23405}}</ref><ref name="pmid28040824">{{cite journal |vauthors=Sorokowska A, Drechsler E, Karwowski M, Hummel T |title=Effects of olfactory training: a meta-analysis |journal=Rhinology |volume=55 |issue=1 |pages=17–26 |date=March 2017 |pmid=28040824 |doi=10.4193/Rhin16.195 |url=}}</ref> have been shown to improve objective tests of [[Olfaction|olfactory]] recovery in a small uncontrolled studies of patients with [[COVID-19]] related [[anosmia]], although, further investigation is needed before these therapies can be widely recomended.<ref name="pmid322777512" />
* Olfactory training suggest small to moderate benefit for patients with post-viral [[Olfaction|olfactory]] [[dysfunction]].
*The main problem for the study of [[anosmia]] related to [[COVID-19]] treatment is that the majority of patients do not give importance to this [[symptom]] and recover [[spontaneously]], without [[medical attention]], so little evidence to support [[pharmacotherapy]] exists.<ref name="pmid32466862" /><ref name="pmid15563908">{{cite journal |vauthors=Seiden AM |title=Postviral olfactory loss |journal=Otolaryngol. Clin. North Am. |volume=37 |issue=6 |pages=1159–66 |date=December 2004 |pmid=15563908 |doi=10.1016/j.otc.2004.06.007 |url=}}</ref>
*[[Alpha lipoic acid]] (600 mg/day), [[omega-3]] supplementation (2000mg/day),and intranasal [[Vitamin A derivatives|vitamin A]] (10,000 U/day)have been shown to improve objective tests of [[Olfaction|olfactory]] recovery in a small uncontrolled studies of patients with [[COVID-19]] related [[anosmia]], although, further investigation is needed before these therapies can be widely recomended.
*The main problem for the study of [[anosmia]] related to [[COVID-19]] treatment is that the majority of patients do not give importance to this [[symptom]] and recover [[spontaneously]], without [[medical attention]], so little evidence to support [[pharmacotherapy]] exists.
*To view medical treatment for COVID-19, click here.
*To view medical treatment for COVID-19, click here.


Line 288: Line 311:
==References==
==References==
{{reflist|2}}
{{reflist|2}}
[[Category:Up-To-Date]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 18:24, 26 November 2021

WikiDoc Resources for COVID-19-associated anosmia

Articles

Most recent articles on COVID-19-associated anosmia

Most cited articles on COVID-19-associated anosmia

Review articles on COVID-19-associated anosmia

Articles on COVID-19-associated anosmia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on COVID-19-associated anosmia

Images of COVID-19-associated anosmia

Photos of COVID-19-associated anosmia

Podcasts & MP3s on COVID-19-associated anosmia

Videos on COVID-19-associated anosmia

Evidence Based Medicine

Cochrane Collaboration on COVID-19-associated anosmia

Bandolier on COVID-19-associated anosmia

TRIP on COVID-19-associated anosmia

Clinical Trials

Ongoing Trials on COVID-19-associated anosmia at Clinical Trials.gov

Trial results on COVID-19-associated anosmia

Clinical Trials on COVID-19-associated anosmia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on COVID-19-associated anosmia

NICE Guidance on COVID-19-associated anosmia

NHS PRODIGY Guidance

FDA on COVID-19-associated anosmia

CDC on COVID-19-associated anosmia

Books

Books on COVID-19-associated anosmia

News

COVID-19-associated anosmia in the news

Be alerted to news on COVID-19-associated anosmia

News trends on COVID-19-associated anosmia

Commentary

Blogs on COVID-19-associated anosmia

Definitions

Definitions of COVID-19-associated anosmia

Patient Resources / Community

Patient resources on COVID-19-associated anosmia

Discussion groups on COVID-19-associated anosmia

Patient Handouts on COVID-19-associated anosmia

Directions to Hospitals Treating COVID-19-associated anosmia

Risk calculators and risk factors for COVID-19-associated anosmia

Healthcare Provider Resources

Symptoms of COVID-19-associated anosmia

Causes & Risk Factors for COVID-19-associated anosmia

Diagnostic studies for COVID-19-associated anosmia

Treatment of COVID-19-associated anosmia

Continuing Medical Education (CME)

CME Programs on COVID-19-associated anosmia

International

COVID-19-associated anosmia en Espanol

COVID-19-associated anosmia en Francais

Business

COVID-19-associated anosmia in the Marketplace

Patents on COVID-19-associated anosmia

Experimental / Informatics

List of terms related to COVID-19-associated anosmia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D. Fahimeh Shojaei, M.D.

Synonyms and keywords: anosmia, olfactory dysfunction, SARS-CoV-2, dysgeusia

Overview

Total or parcial loss of olfactory function (anosmia/hyposmia) has been formally recognized as a characteristic symptom of COVID-19 infection, and may be the most common sign of infection due to this virus. Anosmia may appear without any other symptoms or signs in patients with COVID-19 infection. The extent of potential olfactory dysfunction due to COVID-19 is still unclear. Female gender and advanced age are risk factors for developing anosmia related to COVID-19. Anosmia related to COVID-19, typically has a duration of 8.96 days.

To view the complete page of COVID-19, click here.

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating COVID-19-associated anosmia from other Diseases

Epidemiology and Demographics

Prevalence of anosmia in patients with COVID-19[1]
Date of publication Country Author Number of patients Prevalence
March 26, 2020 Italy Giacomelli et al.[22] 59 33.9%
March 27, 2020 Iran Bagheri et al.[23] 10,069 48.23%
April 1, 2020 Italy Vaira et al.[24] 320 19.4%
April 6, 2020 European countries Lechien et al.[25] 417 85.6%
April 7, 2020 United Kingdom Menni et al.[26] 579 59.41%
April 12, 2020 United States Yan et al.[27] 59 68%
April 16, 2020 France Klopfenstein et al.[28] 47 47%
April 17, 2020 Iran Moein et al.[2] 60 98.33%
April 22, 2020 United Kingdom Spinato et al.[29] 202 64.4%
April 22, 2020 Iran Heidari et al.[30] 23 69.57%
April 22, 2020 Spain Beltran-Corbellini et al.[31] 79 31.65%
April 24, 2020 United States Yan et al.[32] 169 75.7%
May 1, 2020 Germany Luers et al.[33] 72 74%
May 1, 2020 Italy Vaira et al.[34] 33 75.8%


Risk Factors

Screening

Natural History, Complications, and Prognosis

  • Early clinical features before developing anosmia related to COVID-19 include cough, fever, and arthralgias.
  • Anosmia related to COVID-19, typically has a duration of 8.96 days.[1][45]
  • Approximately 82% of patients with anosmia related to COVID-19 recover within 2 weeks and 98% of them within 28 days.[1][45][46]
  • The intensity and duration of the olfactory disfunction associated to COVID-19, is highly variable depending on the capacity and rate of regeneration of the neuroepitielium.[5]
  • A recent review by JAMA showed that 96% of the patients recover from anosmia within one year of its onset. At 6 months, 85% of the patients recovered from anosmia. Parosmia was not evaluated, and it can be potentially more debilitating for patients.[47]
  • To view natural history, complications, and prognosis of COVID-19, click here.

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Common Symptoms

Less Common Symptoms

  • To view the history and symptoms of COVID-19, click here.

Physical Examination

HEENT
    • Closely inspect the nasal cavity and paranasal sinuses to look for polyps or neoplasms.[20]
    • Complete a neurological examination for neurodegenerative disorders.[20]
    • Do a fundoscopy for evidence of raised intracranial pressure due to head trauma.[20]
    • Do skin prick testing for allergic rhinitis.[20]
  • To view the complete physical examination in COVID-19, click here.

Laboratory Findings

Electrocardiogram

X-ray

  • X-ray imaging to the nasal cavity and sinus (Cadwell and Waters projections) does not demonstrate any typical findings in patients with anosmia due to COVID-19, but may be used to exclude other causes
  • To view the x-ray finidings on COVID-19, click here.

Echocardiography or Ultrasound

CT scan

MRI

  • MRI imaging to the nasal cavity and sinus does not demonstrate any typical findings in patients with anosmia due to COVID-19 but may be used to exclude other causes.
  • To view the MRI findings on COVID-19, click here.

Other Imaging Findings

  • Ultrasound imaging to the nasal cavity and sinus does not demonstrate any typical findings in patients with anosmia due to COVID-19 but may be used to exclude other causes.
  • To view other imaging findings on COVID-19, click here.

Other Diagnostic Studies

  • To view other diagnostic studies for COVID-19, click here.

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention


References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 1.22 Meng X, Deng Y, Dai Z, Meng Z (June 2020). "COVID-19 and anosmia: A review based on up-to-date knowledge". Am J Otolaryngol. 41 (5): 102581. doi:10.1016/j.amjoto.2020.102581. PMC 7265845 Check |pmc= value (help). PMID 32563019 Check |pmid= value (help).
  2. ↑ 2.0 2.1 2.2 Moein, Shima T.; Hashemian, Seyed MohammadReza; Mansourafshar, Babak; Khorram‐Tousi, Ali; Tabarsi, Payam; Doty, Richard L. (2020). "Smell dysfunction: a biomarker for COVID‐19". International Forum of Allergy & Rhinology. doi:10.1002/alr.22587. ISSN 2042-6976.
  3. ↑ "[2004.09338] Augmented Curation of Unstructured Clinical Notes from a Massive EHR System Reveals Specific Phenotypic Signature of Impending COVID-19 Diagnosis".
  4. ↑ Beltrán‐Corbellini, Á.; Chico‐García, J. L.; Martínez‐Poles, J.; Rodríguez‐Jorge, F.; Natera‐Villalba, E.; Gómez‐Corral, J.; Gómez‐López, A.; Monreal, E.; Parra‐Díaz, P.; Cortés‐Cuevas, J. L.; Galán, J. C.; Fragola‐Arnau, C.; Porta‐Etessam, J.; Masjuan, J.; Alonso‐Cánovas, A. (2020). "Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study". European Journal of Neurology. doi:10.1111/ene.14273. ISSN 1351-5101.
  5. ↑ 5.00 5.01 5.02 5.03 5.04 5.05 5.06 5.07 5.08 5.09 5.10 5.11 5.12 Lop Gros J, Iglesias Coma M, González Farré M, Serra Pujadas C (May 2020). "Olfactory dysfunction in COVID-19, a review of the evidence and implications for pandemic management". Acta Otorrinolaringol Esp. doi:10.1016/j.otorri.2020.04.003. PMID 32466862 Check |pmid= value (help).
  6. ↑ Hummel T, Whitcroft KL, Andrews P, Altundag A, Cinghi C, Costanzo RM, Damm M, Frasnelli J, Gudziol H, Gupta N, Haehne A, Holbrook E, Hong SC, Hornung D, Hüttenbrink KB, Kamel R, Kobayashi M, Konstantinidis I, Landis BN, Leopold DA, Macchi A, Miwa T, Moesges R, Mullol J, Mueller CA, Ottaviano G, Passali GC, Philpott C, Pinto JM, Ramakrishnan VJ, Rombaux P, Roth Y, Schlosser RA, Shu B, Soler G, Stjärne P, Stuck BA, Vodicka J, Welge-Luessen A (March 2017). "Position paper on olfactory dysfunction". Rhinol. Suppl. 54 (26): 1–30. doi:10.4193/Rhino16.248. PMID 29528615.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 7.7 7.8 Hopkins C, Surda P, Kumar N (June 2020). "Presentation of new onset anosmia during the COVID-19 pandemic". Rhinology. 58 (3): 295–298. doi:10.4193/Rhin20.116. PMID 32277751 Check |pmid= value (help).
  8. ↑ Eccles R (November 2005). "Understanding the symptoms of the common cold and influenza". Lancet Infect Dis. 5 (11): 718–25. doi:10.1016/S1473-3099(05)70270-X. PMC 7185637 Check |pmc= value (help). PMID 16253889.
  9. ↑ Rockx B, Kuiken T, Herfst S, Bestebroer T, Lamers MM, Oude Munnink BB, de Meulder D, van Amerongen G, van den Brand J, Okba N, Schipper D, van Run P, Leijten L, Sikkema R, Verschoor E, Verstrepen B, Bogers W, Langermans J, Drosten C, Fentener van Vlissingen M, Fouchier R, de Swart R, Koopmans M, Haagmans BL (May 2020). "Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model". Science. 368 (6494): 1012–1015. doi:10.1126/science.abb7314. PMC 7164679 Check |pmc= value (help). PMID 32303590 Check |pmid= value (help). Vancouver style error: initials (help)
  10. ↑ Forster, Peter; Forster, Lucy; Renfrew, Colin; Forster, Michael (2020). "Phylogenetic network analysis of SARS-CoV-2 genomes". Proceedings of the National Academy of Sciences. 117 (17): 9241–9243. doi:10.1073/pnas.2004999117. ISSN 0027-8424.
  11. ↑ Baig AM, Khaleeq A, Ali U, Syeda H (April 2020). "Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms". ACS Chem Neurosci. 11 (7): 995–998. doi:10.1021/acschemneuro.0c00122. PMC 7094171 Check |pmc= value (help). PMID 32167747 Check |pmid= value (help).
  12. ↑ Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q, Song T, He J, Yen HL, Peiris M, Wu J (March 2020). "SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients". N. Engl. J. Med. 382 (12): 1177–1179. doi:10.1056/NEJMc2001737. PMC 7121626 Check |pmc= value (help). PMID 32074444 Check |pmid= value (help).
  13. ↑ 13.0 13.1 13.2 Dubé M, Le Coupanec A, Wong A, Rini JM, Desforges M, Talbot PJ (September 2018). "Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43". J. Virol. 92 (17). doi:10.1128/JVI.00404-18. PMC 6096804. PMID 29925652. Vancouver style error: initials (help)
  14. ↑ Koyuncu OO, Hogue IB, Enquist LW (April 2013). "Virus infections in the nervous system". Cell Host Microbe. 13 (4): 379–93. doi:10.1016/j.chom.2013.03.010. PMC 3647473. PMID 23601101.
  15. ↑ Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, Talavera-López C, Maatz H, Reichart D, Sampaziotis F, Worlock KB, Yoshida M, Barnes JL (May 2020). "SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes". Nat. Med. 26 (5): 681–687. doi:10.1038/s41591-020-0868-6. PMID 32327758 Check |pmid= value (help).
  16. ↑ Capelli, Marco; Gatti, Patrizia (2020). "Anosmia and COVID-19 in south Lombardy: description of the first cases series in Europe". B-ENT. 16 (1): 86–90. doi:10.5152/B-ENT.2020.20129. ISSN 2684-4907.
  17. ↑ Yao, Hangping; Lu, Xiangyun; Chen, Qiong; Xu, Kaijin; Chen, Yu; Cheng, Linfang; Liu, Fumin; Wu, Zhigang; Wu, Haibo; Jin, Changzhong; Zheng, Min; Wu, Nanping; Jiang, Chao; Li, Lanjuan (2020). doi:10.1101/2020.04.14.20060160. Missing or empty |title= (help)
  18. ↑ "www.thelancet.com".
  19. ↑ Suzuki M, Saito K, Min WP, Vladau C, Toida K, Itoh H, Murakami S (February 2007). "Identification of viruses in patients with postviral olfactory dysfunction". Laryngoscope. 117 (2): 272–7. doi:10.1097/01.mlg.0000249922.37381.1e. PMC 7165544 Check |pmc= value (help). PMID 17277621.
  20. ↑ 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 "Anosmia - StatPearls - NCBI Bookshelf".
  21. ↑ Menni, Cristina; Valdes, Ana; Freydin, Maxim B; Ganesh, Sajaysurya; El-Sayed Moustafa, Julia; Visconti, Alessia; Hysi, Pirro; Bowyer, Ruth C E; Mangino, Massimo; Falchi, Mario; Wolf, Jonathan; Steves, Claire; Spector, Tim (2020). doi:10.1101/2020.04.05.20048421. Missing or empty |title= (help)
  22. ↑ Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S, Galli M (March 2020). "Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study". Clin. Infect. Dis. doi:10.1093/cid/ciaa330. PMC 7184514 Check |pmc= value (help). PMID 32215618 Check |pmid= value (help).
  23. ↑ Bagheri, Seyed Hamid Reza; Asghari, Ali Mohammad; Farhadi, Mohammad; Shamshiri, Ahmad Reza; Kabir, Ali; Kamrava, Seyed Kamran; Jalessi, Maryam; Mohebbi, Alireza; Alizadeh, Rafieh; Honarmand, Ali Asghar; Ghalehbaghi, Babak; Salimi, Alireza (2020). doi:10.1101/2020.03.23.20041889. Missing or empty |title= (help)
  24. ↑ Vaira LA, Salzano G, Deiana G, De Riu G (July 2020). "Anosmia and Ageusia: Common Findings in COVID-19 Patients". Laryngoscope. 130 (7): 1787. doi:10.1002/lary.28692. PMC 7228304 Check |pmc= value (help). PMID 32237238 Check |pmid= value (help).
  25. ↑ Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, Dequanter D, Blecic S, El Afia F, Distinguin L, Chekkoury-Idrissi Y, Hans S, Delgado IL, Calvo-Henriquez C, Lavigne P, Falanga C, Barillari MR, Cammaroto G, Khalife M, Leich P, Souchay C, Rossi C, Journe F, Hsieh J, Edjlali M, Carlier R, Ris L, Lovato A, De Filippis C, Coppee F, Fakhry N, Ayad T, Saussez S (April 2020). "Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study". Eur Arch Otorhinolaryngol. doi:10.1007/s00405-020-05965-1. PMC 7134551 Check |pmc= value (help). PMID 32253535 Check |pmid= value (help).
  26. ↑ Menni, Cristina; Valdes, Ana; Freydin, Maxim B; Ganesh, Sajaysurya; El-Sayed Moustafa, Julia; Visconti, Alessia; Hysi, Pirro; Bowyer, Ruth C E; Mangino, Massimo; Falchi, Mario; Wolf, Jonathan; Steves, Claire; Spector, Tim (2020). doi:10.1101/2020.04.05.20048421. Missing or empty |title= (help)
  27. ↑ Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS (April 2020). "Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms". Int Forum Allergy Rhinol. doi:10.1002/alr.22579. PMC 7262089 Check |pmc= value (help). PMID 32279441 Check |pmid= value (help).
  28. ↑ Klopfenstein, T.; Kadiane-Oussou, N.J.; Toko, L.; Royer, P.-Y.; Lepiller, Q.; Gendrin, V.; Zayet, S. (2020). "Features of anosmia in COVID-19". Médecine et Maladies Infectieuses. doi:10.1016/j.medmal.2020.04.006. ISSN 0399-077X.
  29. ↑ Spinato, Giacomo; Fabbris, Cristoforo; Polesel, Jerry; Cazzador, Diego; Borsetto, Daniele; Hopkins, Claire; Boscolo-Rizzo, Paolo (2020). "Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection". JAMA. 323 (20): 2089. doi:10.1001/jama.2020.6771. ISSN 0098-7484.
  30. ↑ Heidari, F.; Karimi, E.; Firouzifar, M.; Khamushian, P.; Ansari, R.; Mohammadi Ardehali, M.; Heidari, F. (2020). "Anosmia as a Prominent Symptom of COVID-19 Infection". Rhinology journal. 58 (3): 302–303. doi:10.4193/Rhin20.140. ISSN 0300-0729.
  31. ↑ Beltrán‐Corbellini, Á.; Chico‐García, J. L.; Martínez‐Poles, J.; Rodríguez‐Jorge, F.; Natera‐Villalba, E.; Gómez‐Corral, J.; Gómez‐López, A.; Monreal, E.; Parra‐Díaz, P.; Cortés‐Cuevas, J. L.; Galán, J. C.; Fragola‐Arnau, C.; Porta‐Etessam, J.; Masjuan, J.; Alonso‐Cánovas, A. (2020). "Acute‐onset smell and taste disorders in the context of COVID‐19: a pilot multicentre polymerase chain reaction based case–control study". European Journal of Neurology. doi:10.1111/ene.14273. ISSN 1351-5101.
  32. ↑ Yan, Carol H.; Faraji, Farhoud; Prajapati, Divya P.; Ostrander, Benjamin T.; DeConde, Adam S. (2020). "Self‐reported olfactory loss associates with outpatient clinical course in COVID‐19". International Forum of Allergy & Rhinology. doi:10.1002/alr.22592. ISSN 2042-6976.
  33. ↑ Heindl, Ludwig M; Lehmann, Clara; Klein, Florian; Dewald, Felix; Augustin, Max; Wawer Matos, Philomena A; Loreck, Niklas; Rokohl, Alexander C; Luers, Jan C (2020). "Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19)". Clinical Infectious Diseases. doi:10.1093/cid/ciaa525. ISSN 1058-4838.
  34. ↑ Vaira, Luigi Angelo; Salzano, Giovanni; Petrocelli, Marzia; Deiana, Giovanna; Salzano, Francesco Antonio; De Riu, Giacomo (2020). "Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine". Head & Neck. doi:10.1002/hed.26228. ISSN 1043-3074.
  35. ↑ Zhu N, Zhang D, Wang W et al. A Novel Welge -Lussen A, Wolfensberger M. (2006). "Olfactory disorders following upper respiratory tract infections". Adv Otorhinolaryngol.
  36. ↑ Brämerson A, Johansson L, Ek L, Nordin S, Bende M (April 2004). "Prevalence of olfactory dysfunction: the skövde population-based study". Laryngoscope. 114 (4): 733–7. doi:10.1097/00005537-200404000-00026. PMID 15064632.
  37. ↑ 37.0 37.1 Stogbauer J, Wirkner K, Engel C, Moebus S, Pundt N, Teismann H, Loffler M, Hummel T, Beule AG, Berger K (April 2020). "Prevalence and risk factors of smell dysfunction - a comparison between five German population-based studies". Rhinology. 58 (2): 184–191. doi:10.4193/Rhin19.181. PMID 31693018.
  38. ↑ 38.0 38.1 Wang X, Zhang C, Xia X, Yang Y, Zhou C (October 2019). "Effect of gender on odor identification at different life stages: a meta-analysis". Rhinology. 57 (5): 322–330. doi:10.4193/Rhin19.005. PMID 31152646.
  39. ↑ Williams, Frances MK; Freydin, Maxim; Mangino, Massimo; Couvreur, Simon; Visconti, Alessia; Bowyer, Ruth CE; Le Roy, Caroline I; Falchi, Mario; Sudre, Carole; Davies, Richard; Hammond, Christopher; Menni, Cristina; Steves, Claire; Spector, Tim (2020). doi:10.1101/2020.04.22.20072124. Missing or empty |title= (help)
  40. ↑ Nguyen DT, Rumeau C, Gallet P, Jankowski R (April 2016). "Olfactory exploration: State of the art". Eur Ann Otorhinolaryngol Head Neck Dis. 133 (2): 113–8. doi:10.1016/j.anorl.2015.08.038. PMID 26384780.
  41. ↑ Simopoulos E, Katotomichelakis M, Gouveris H, Tripsianis G, Livaditis M, Danielides V (July 2012). "Olfaction-associated quality of life in chronic rhinosinusitis: adaptation and validation of an olfaction-specific questionnaire". Laryngoscope. 122 (7): 1450–4. doi:10.1002/lary.23349. PMID 22566102.
  42. ↑ 42.0 42.1 Robert Pellegrin, Keiland W. Cooper, Antonella Di Pizio, Paule V. Joseph, Surabhi Bhutani, Valentina Parma (2020). "Corona Viruses and the Chemical Senses: Past, Present, and Future". Oxford University. line feed character in |title= at position 40 (help)
  43. ↑ "www.entuk.org" (PDF).
  44. ↑ 44.0 44.1 "AAO-HNSF 2020 Annual Meeting & OTO Experience | American Academy of Otolaryngology-Head and Neck Surgery".
  45. ↑ 45.0 45.1 45.2 Klopfenstein T, Kadiane-Oussou NJ, Toko L, Royer PY, Lepiller Q, Gendrin V, Zayet S (April 2020). "Features of anosmia in COVID-19". Med Mal Infect. doi:10.1016/j.medmal.2020.04.006. PMC 7162775 Check |pmc= value (help). PMID 32305563 Check |pmid= value (help).
  46. ↑ Yan CH, Faraji F, Prajapati DP, Boone CE, DeConde AS (April 2020). "Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms". Int Forum Allergy Rhinol. doi:10.1002/alr.22579. PMC 7262089 Check |pmc= value (help). PMID 32279441 Check |pmid= value (help).
  47. ↑ Renaud M, Thibault C, Le Normand F, Mcdonald EG, Gallix B, Debry C; et al. (2021). "Clinical Outcomes for Patients With Anosmia 1 Year After COVID-19 Diagnosis". JAMA Netw Open. 4 (6): e2115352. doi:10.1001/jamanetworkopen.2021.15352. PMC 8226421 Check |pmc= value (help). PMID 34165581 Check |pmid= value (help).
  48. ↑ Ottaviano, G.; Carecchio, M.; Scarpa, B.; Marchese-Ragona, R. (2020). "Olfactory and rhinological evaluations in SARS-CoV-2 patients complaining of olfactory loss". Rhinology journal. 0 (0): 0–0. doi:10.4193/Rhin20.136. ISSN 0300-0729.
  49. ↑ Vaira, Luigi Angelo; Salzano, Giovanni; Petrocelli, Marzia; Deiana, Giovanna; Salzano, Francesco Antonio; De Riu, Giacomo (2020). "Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine". Head & Neck. doi:10.1002/hed.26228. ISSN 1043-3074.
  50. ↑ Doty RL (2007). "Office procedures for quantitative assessment of olfactory function". Am J Rhinol. 21 (4): 460–73. doi:10.2500/ajr.2007.21.3043. PMID 17882917.
  51. ↑ Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE, Noyce AJ (August 2019). "Screening performance of abbreviated versions of the UPSIT smell test". J. Neurol. 266 (8): 1897–1906. doi:10.1007/s00415-019-09340-x. PMC 6647236 Check |pmc= value (help). PMID 31053960.
  52. ↑ "Neue Corona-Symptome entdeckt: Virologe Hendrik Streeck zum Virus".
  53. ↑ Heidari F, Karimi E, Firouzifar M, Khamushian P, Ansari R, Mohammadi Ardehali M, Heidari F (June 2020). "Anosmia as a prominent symptom of COVID-19 infection". Rhinology. 58 (3): 302–303. doi:10.4193/Rhin20.140. PMID 32319971 Check |pmid= value (help).
  54. ↑ "Coronavirus disease (COVID-19)".
  55. ↑ Hopkins C, Surda P, Kumar N (June 2020). "Presentation of new onset anosmia during the COVID-19 pandemic". Rhinology. 58 (3): 295–298. doi:10.4193/Rhin20.116. PMID 32277751 Check |pmid= value (help).
  56. ↑ 56.0 56.1 Ikeda K, Sakurada T, Suzaki Y, Takasaka T (September 1995). "Efficacy of systemic corticosteroid treatment for anosmia with nasal and paranasal sinus disease". Rhinology. 33 (3): 162–5. PMID 8560170.
  57. ↑ Yan CH, Rathor A, Krook K, Ma Y, Rotella MR, Dodd RL, Hwang PH, Nayak JV, Oyesiku NM, DelGaudio JM, Levy JM, Wise J, Wise SK, Patel ZM (January 2020). "Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial". Neurosurgery. doi:10.1093/neuros/nyz559. PMID 31950156.
  58. ↑ Yan CH, Rathor A, Krook K, Ma Y, Rotella MR, Dodd RL, Hwang PH, Nayak JV, Oyesiku NM, DelGaudio JM, Levy JM, Wise J, Wise SK, Patel ZM (January 2020). "Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Sellar and Parasellar Tumor Resection: A Multicenter Prospective Randomized Controlled Trial". Neurosurgery. doi:10.1093/neuros/nyz559. PMID 31950156.
  59. ↑ Reden, Jens; Lill, Katja; Zahnert, Thomas; Haehner, Antje; Hummel, Thomas (2012). "Olfactory function in patients with postinfectious and posttraumatic smell disorders before and after treatment with vitamin A: A double-blind, placebo-controlled, randomized clinical trial". The Laryngoscope. 122 (9): 1906–1909. doi:10.1002/lary.23405. ISSN 0023-852X.
  60. ↑ Hummel T, Heilmann S, Hüttenbriuk KB (November 2002). "Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract". Laryngoscope. 112 (11): 2076–80. doi:10.1097/00005537-200211000-00031. PMID 12439184.
  61. ↑ Hummel T, Heilmann S, Hüttenbriuk KB (November 2002). "Lipoic acid in the treatment of smell dysfunction following viral infection of the upper respiratory tract". Laryngoscope. 112 (11): 2076–80. doi:10.1097/00005537-200211000-00031. PMID 12439184.
  62. ↑ Sorokowska A, Drechsler E, Karwowski M, Hummel T (March 2017). "Effects of olfactory training: a meta-analysis". Rhinology. 55 (1): 17–26. doi:10.4193/Rhin16.195. PMID 28040824.
  63. ↑ Seiden AM (December 2004). "Postviral olfactory loss". Otolaryngol. Clin. North Am. 37 (6): 1159–66. doi:10.1016/j.otc.2004.06.007. PMID 15563908.
  64. ↑ Meng, Xiangming; Dai, Zhiyong; Hang, Chao; Wang, Yangyang (2020). "Smartphone-enabled wireless otoscope-assisted online telemedicine during the COVID-19 outbreak". American Journal of Otolaryngology. 41 (3): 102476. doi:10.1016/j.amjoto.2020.102476. ISSN 0196-0709.
  65. ↑ Vaira, Luigi Angelo; Salzano, Giovanni; Petrocelli, Marzia; Deiana, Giovanna; Salzano, Francesco Antonio; De Riu, Giacomo (2020). "Validation of a self-administered olfactory and gustatory test for the remotely evaluation of COVID-19 patients in home quarantine". Head & Neck. doi:10.1002/hed.26228. ISSN 1043-3074.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=COVID-19-associated_anosmia&oldid=1716728"